Senator Bill Cassidy Backs Dr. Erica Schwartz for CDC Director Nomination

by

Senator Bill Cassidy signaled his support for Dr. Erica Schwartz to lead the CDC on July 23, 2026, reversing his previous skepticism. The move clears a significant hurdle for President Donald Trump’s nominee, who faces a divided Senate health committee and an agency struggling with leadership turmoil and rising disease outbreaks.

The path to confirmation for Dr. Erica Schwartz shifted on Thursday after the Republican chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee announced he would back her nomination. Senator Bill Cassidy, a physician from Louisiana, had previously expressed disappointment over Schwartz’s refusal to say whether she would defy Health Secretary Robert F. Kennedy Jr. on vaccine policy.

Cassidy’s support is critical. With a thin 12-11 Republican majority on the committee, his vote could be the deciding factor if Democrats remain unanimous in their opposition, a position already taken by ranking member Senator Bernie Sanders.

The Tension Over Vaccine Policy and Secretary Kennedy

The central conflict of Schwartz’s confirmation revolves around the chain of command between the CDC and the Department of Health and Human Services. Senators have spent weeks grilling the nominee on whether she would act as a rubber stamp for Secretary Kennedy’s agenda, which Senator Sanders described as a very dangerous agenda to limit the use of safe and effective vaccines.

During her July 15 hearing, Schwartz attempted to balance her commitment to science with her loyalty to the administration. While she vowed to never betray the science, she repeatedly avoided giving “yes or no” answers to hypothetical scenarios regarding political interference.

“If confirmed, my first priority will be restoring trust in public health institutions through radical transparency and unwavering scientific integrity.”

Dr. Erica Schwartz, CDC Nominee

The friction became most apparent when Senator Maggie Hassan questioned Schwartz about a 2025 incident where Kennedy canceled a CDC campaign to promote flu vaccines during a season that saw nearly 300 children die. When asked if she would refuse a similar order in the future, Schwartz responded, I don’t speak in hypotheticals.

A Legacy of Leadership Turmoil and Agency Vacancies

Schwartz is stepping into a role defined by instability. The previous confirmed director, Dr. Susan Monarez, was fired less than a month into her tenure after clashing with Secretary Kennedy over vaccine recommendations and the firing of career scientists.

Erica Schwartz, President Donald Trump
Photo: Reuters

This leadership vacuum has coincided with severe public health challenges.

  • An international Ebola outbreak in the Democratic Republic of the Congo and Uganda.
  • A nationwide outbreak of explosive diarrhea caused by Cyclospora infections that has sickened nearly 7,000 people.

The instability isn’t just at the top. Senator Lisa Blunt Rochester noted that many highly qualified officials have either quit or been forced to change positions, leaving numerous leadership roles vacant.

Schwartz’s Qualifications and Professional Backing

Despite the political firestorm, Schwartz possesses a deep resume in public health and military service. A board-certified preventive medicine physician and retired rear admiral in the U.S. Public Health Service Commissioned Corps, she previously served as the chief medical officer of the U.S. Coast Guard and as deputy surgeon general during Trump’s first term.

Sen. Cassidy backs CDC director nominee Erica Schwartz

Her professional standing has earned her support from former health officials. Dr. Debra Houry, the CDC’s former chief medical officer who resigned after Monarez’s firing, told Time that Schwartz has the right qualifications for the position.

However, her hearing revealed significant gaps in her awareness of recent agency decisions. When questioned by Senator Patty Murray, Schwartz claimed she was unaware of the decision to make tracking Cyclospora cases optional rather than mandatory, and she was equally unfamiliar with the elimination of nearly $500 million in contracts for mRNA vaccine development.

The committee has postponed the vote until next week due to attendance issues. If the nomination advances, the full Senate will decide whether Schwartz can provide the stable, independent leadership the agency requires to combat current outbreaks while navigating the priorities of the HHS Secretary.

Worth a look

Read next